All Stories

  1. NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties
  2. Lollipop Plots to Communicate Cost-Effectiveness Scenario Analyses Results
  3. Reply to Comment on “Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective”
  4. The Cost-Effectiveness of an Artificial Intelligence-Based Population-Wide Screening Program for Primary Open-Angle Glaucoma in The Netherlands
  5. Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective
  6. When Evidence Falls Short—Belzutifan for Treating Tumours Associated with von Hippel-Lindau Disease: An External Assessment Group Perspective on a NICE Single Technology Appraisal
  7. Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review
  8. The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study
  9. Beyond hazard ratios: appropriate statistical methods for quantifying the clinical effectiveness of immune-oncology therapies – the example of the Netherlands
  10. A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model
  11. Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy
  12. Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling
  13. A blueprint for health technology assessment capacity building: lessons learned from Malta
  14. SeHCAT (tauroselcholic [75selenium] acid) for the investigation of bile acid diarrhoea in adults: a systematic review and cost-effectiveness analysis
  15. Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis
  16. The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis
  17. Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
  18. Four Aspects Affecting Health Economic Decision Models and Their Validation
  19. Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure
  20. Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy
  21. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study
  22. Cost-effectiveness of a home telemonitoring system and a diagnostic algorithm in the management of heart failure in the Netherlands (Preprint)
  23. Cost-utility analysis of four common surgical treatment pathways for breast cancer
  24. How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease
  25. Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients
  26. Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE)
  27. What Is the Potential of Tissue-Engineered Pulmonary Valves in Children?
  28. Severity-Adjusted Probability of Being Cost Effective
  29. Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine
  30. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
  31. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
  32. PRM120 - GRAPHICAL USER-FRIENDLY INTERFACE FOR COMPLEX HEALTH ECONOMIC MODELS BUILT IN R
  33. PRS49 - COST-EFFECTIVENESS OF THE FIXED-DOSE COMBINATION TIOTROPIUM + OLODATEROL VERSUS TIOTROPIUM BASED ON THE DYNAGITO TRIAL RESULTS IN FRANCE
  34. PCV92 - EARLY HEALTH TECHNOLOGY ASSESSMENT OF TISSUE-ENGINEERED HEART VALVES IN THE AORTIC POSITION IN ELDERLY PATIENTS
  35. PHP142 - SEVERITY ADJUSTED PROBABILITY OF BEING COST-EFFECTIVE: A NOVEL APPROACH TO INTEGRATE SEVERITY AND COST-EFFECTIVENESS WITH APPLICATIONS TO NORWAY AND THE NETHERLANDS
  36. Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results
  37. The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios
  38. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmaco...
  39. Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance
  40. Early Modelling of The Cost-Effectiveness of Stratified Medicine In COPD
  41. Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
  42. Modeling the cost-effectiveness of stratified medicine in COPD
  43. A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data
  44. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis
  45. Estimating Study Costs For Use In Voi, A Study Of Dutch Publicly Funded Drug Related Research
  46. The Increasing Importance of A Continence Nurse Specialist To Improve Outcomes And Save Costs of Urinary Incontinence Care: An Analysis of Future Policy Scenarios
  47. Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework
  48. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evalua...
  49. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
  50. Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
  51. Operational Validation of Health Economic Decision Analytic Models
  52. The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling
  53. Costs of Hospital Stay in Specialized Diabetic Foot Department in Russia
  54. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
  55. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis
  56. Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis
  57. Prioritization of Future Outcomes Research Studies in Chronic Myeloid Leukemia: Value of Information Analysis
  58. Advishe: a New Tool to Report Validation of Health-Economic Decision Models
  59. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis
  60. Cost for Treatment of Chronic Lymphocytic Leukemia in Specialized Institutions of Ukraine
  61. Improving Model Validation in Health Technology Assessment: Comments on Guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force
  62. Dead-locks and Break of Symmetry in Robot Coordination
  63. The Role of Value-of-Information Analysis in a Health Care Research Priority Setting
  64. VI1 Determining the Impact of Modeling Additional Sources of Uncertainty in Value of Information Analysis
  65. PHP104 Identifying Factors Influencing Drug Reimbursement in Scotland
  66. PHP87 THE ROLE OF VALUE OF INFORMATION ANALYSIS IN HEALTH CARE RESEARCH PRIORITY SETTING:A THEORETICAL CASE STUDY
  67. Model Driven Testing Based on Test History
  68. Two Case Studies in Applying Statistical Models in Software Development